相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
Sevda Jafari et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells
Sevda Jafari et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin
Samira Khaledi et al.
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION (2020)
Poly(ethylene glycol)-poly(epsilon-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin
Ashkan Hassankhani Rad et al.
BIOIMPACTS (2020)
Natural compound inducers of immunogenic cell death
Marc Diederich
ARCHIVES OF PHARMACAL RESEARCH (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy
Flavia Radogna et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Silibinin is a direct inhibitor of STAT3
Sara Verdura et al.
FOOD AND CHEMICAL TOXICOLOGY (2018)
Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development
Barbara Montico et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines
Yuanxin Zhang et al.
MOLECULAR MEDICINE REPORTS (2018)
The inducers of immunogenic cell death for tumor immunotherapy
Xiuying Li
TUMORI JOURNAL (2018)
The inducers of immunogenic cell death for tumor immunotherapy
Xiuying Li
TUMORI JOURNAL (2018)
Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy
Ommoleila Molavi et al.
PHARMACEUTICAL BIOLOGY (2017)
Self-Associating Poly(ethylene oxide)-block-poly(α-carboxyl-ε-caprolactone) Drug Conjugates for the Delivery of STAT3 Inhibitor JSI-124: Potential Application in Cancer Immunotherapy
Shyam M. Garg et al.
MOLECULAR PHARMACEUTICS (2017)
Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells
Hyo Joo Byun et al.
ONCOLOGY REPORTS (2017)
Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative
Keum-joo Son et al.
PLOS ONE (2017)
Targeting STAT3 with silibinin to improve cancer therapeutics
Joaquim Bosch-Barrera et al.
CANCER TREATMENT REVIEWS (2017)
STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis
Laura M. Jones et al.
CANCER RESEARCH (2016)
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
Heng Yang et al.
CANCER RESEARCH (2015)
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
Joaquim Bosch-Barrera et al.
CANCER TREATMENT REVIEWS (2015)
Combinatorial strategies for the induction of immunogenic cell death
Lucillia Bezu et al.
FRONTIERS IN IMMUNOLOGY (2015)
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
Hongliang Fang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
Christel Devaud et al.
ONCOIMMUNOLOGY (2013)
Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis
Henriette Kauntz et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers
Xiaochun Wang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Stephen R. Mattarollo et al.
CANCER RESEARCH (2011)
Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma
Miki Tongu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity
Laetitia Aymeric et al.
CANCER RESEARCH (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
T. Panaretakis et al.
CELL DEATH AND DIFFERENTIATION (2008)
Immune modulation by melanoma-derived factors
Dan Ilkovitch et al.
EXPERIMENTAL DERMATOLOGY (2008)
IL-12 Produced by Dendritic Cells Augments CD8+ T Cell Activation through the Production of the Chemokines CCL1 and CCL17
Curtis J. Henry et al.
JOURNAL OF IMMUNOLOGY (2008)
Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms
Komal Raina et al.
ACTA PHARMACOLOGICA SINICA (2007)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype
YW Eom et al.
ONCOGENE (2005)
Oral Silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducible chemoresistance
RP Singh et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
